Pancreatic Polypeptide (Serial Monitor)
Use
The Pancreatic Polypeptide (Serial Monitor) test is utilized for long-term serial monitoring of pancreatic polypeptide levels, which can provide valuable insights in the management of patients undergoing therapy. It can be particularly useful in assessing the effectiveness of treatment strategies over time. The test results, combined with clinical evaluations, help in adjusting therapeutic approaches as needed in various clinical scenarios, including disorders affecting the pancreas.
Special Instructions
The account must submit the patient's Social Security number to monitor. Values obtained with different assay methods should not be used interchangeably in serial testing. It is recommended that only one assay method be used consistently to monitor each patient's course of therapy.
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Assay results should not be interpreted as absolute evidence of the presence or absence of malignant disease. Values obtained with different assay methods or kits cannot be used interchangeably.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 2721-9
- 2721-9
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided